Late last month Congress passed a nearly 5,600-page legislative package that included $900 billion for urgent pandemic relief, a ban on surprise medical bills and other non-COVID health care issues.
During the 2020 State of the Union address, President Donald Trump zeroed in on prescription drug prices, arguing that his administration is “taking on the big pharmaceutical companies.”
In the heat of the most ferocious battle over drug prices in years, pharmaceutical companies are showering U.S. senators with campaign cash as sweeping legislation heads toward the floor.
For the first time since passing the Affordable Care Act, Democrats will soon control the House of Representatives and its powerful health committees. But Republicans’ tightened grip on the Senate means those hoping for another round of dramatic, progressive reforms may be disappointed.